SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

SRT1720 Chemical Structure

SRT1720 Chemical Structure
Molecular Weight: 506.02

Validation & Quality Control

Customer Product Validation(5)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Sirtuin Inhibitors & Activators
    Compare Sirtuin Products
  • Research Area

Product Description

Biological Activity

Description SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.
Targets SIRT1 [1]
(Cell-free assay)
IC50 0.16 μM(EC50)
In vitro The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol(Only for Reference)

Kinase Assay: [1]

SIRT1 fluorescence polarization assay In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.

Cell Assay: [2]

Cell lines Human vascular endothelial cells (HUVECs)
Concentrations 5 μM
Incubation Time 2 hours
Method Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.

Animal Study: [1]

Animal Models Chase-SCID mice with MM.1S cells
Formulation 20% PEG400/0.5% Tween80/79.5% deionized water
Dosages 200 mg/kg
Administration Orally

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Milne JC, et al. Nature. 2007, 450(7170), 712-716.

[2] Chauhan D, et al. Br J Haematol. 2011, 155(5), 588-598.

Chemical Information

Download SRT1720 SDF
Molecular Weight (MW) 506.02


CAS No. 1001645-58-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 38 mg/mL (75.09 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydrochloride

Customer Product Validation (5)

Click to enlarge
Source EMBO J 2013 32, 791-804. SRT1720 purchased from Selleck
Method Western blots
Cell Lines 293T cells
Concentrations 20 μM
Incubation Time 4 h
Results Treatment with SIRT1 activator resveratrol or SRT1720 reduced Ubc9 acetylation(Figure D). 293T cells treated with SRT1720 showed increased Elk-1 sumoylation (Figure H). treatment of SRT1720 failed to enhance Elk-1 sumoylation in Ubc9 K65R-transfected cells, compared to Ubc9 WT-transfected cells (Figure I).

Click to enlarge
Source J Neurosci 2014 34(36), 11897-912. SRT1720 purchased from Selleck
Cell Lines IRF9-KO, IRF9-TG mice
Concentrations 30 ug
Incubation Time 24 h
Results Importantly, the intracranial injection of SRT1720 into IRF9-KO mice or IRF9-TG mice, recapitulated its observations in the IRF9/Sirt1-DKO or -DTG mice with respect to stroke outcome. These findings indicate that IRF9 is a previously unrecognized negative regulator of the Sirt1/p53 axis. Furthermore, our results show that the IRF9-Sirt1-p53 axis is functionally necessary for ischemic cerebral injury.

Click to enlarge
Source Aging Cell 2014 13(5), 890-9. SRT1720 purchased from Selleck
Method qPCR, Western blot
Cell Lines senescent HUVECs
Incubation Time 24, 48 h
Results Conversely, treatment of senescent HUVECs with SRT1720, a SIRT1-specific activator, significantly inhibited PAI-1 expression at both the mRNA and protein levels (D–F). Previous studies have shown that SIRT1 inhibition induces endothelial cell senescence.

Click to enlarge
Source J Biol Chem 2014 289(29), 20012-25. SRT1720 purchased from Selleck
Cell Lines C2C12 cells
Concentrations 2 uM
Incubation Time 4 days
Results It tested whether the enhancement of NDUFV1 knockdown-induced myogenesis was abolished after activating SIRT1 by treating NDUFV1-knockdown myotubes with SIRT1 activators such as pyruvate, SRT1720, and resveratrol. It then monitored myogenesis using MyHC immunofluorescence for myogenic marker proteins. As shown in Figure, SRT1720 abolished the enhancement of NDUFV1 knockdown-induced myogenesis. These data suggest that the enhancement of NDUFV1-induced myogenesis results from lowering the NAD+/NADH ratio and inactivating SIRT1.

Click to enlarge
Source J Biol Chem 2012 287, 19304-19314. SRT1720 purchased from Selleck
Method Flow cytometric quantification
Cell Lines Human fibroblasts
Concentrations 80-800 nM
Incubation Time 1-7 d
Results Treatment with fisetin or SRT1720 caused a decrease of the mitochondrial content to levels similar to that achieved by NAM treatment.

Product Use Citation (15)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Sirtuin Products

  • AGK2

    AGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM.

  • Splitomicin

    Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 μM, showing a higher activity in a cell-based assay.

  • SRT2104 (GSK2245840)

    SRT2104 (GSK2245840) is a selective SIRT1 activator involved in the regulation of energy homeostasis. Phase 2.

  • Resveratrol

    Resveratrol is a phytoalexin produced naturally by several plants with anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects.

  • EX 527 (Selisistat)

    EX 527 is a potent and selective SIRT1 inhibitor with IC50 of 38 nM in a cell-free assay, exhibits >200-fold selectivity against SIRT2 and SIRT3.

    Features:Greater potency, specificity, stability, and lower toxicity than other inhibitors of SIRT1 catalytic activity identified to date.

  • Nicotinamide (Vitamin B3)

    Nicotinamide (Vitamin B3), a water-soluble vitamin, is an active component of coenzymes NAD and NADP, and also act as an inhibitor of sirtuins.

  • Fisetin

    Fisetin (Fustel) is a potent sirtuin activating compound (STAC) and an agent that modulates sirtuins.

  • Quercetin

    Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM. Phase 4.

  • Sirtinol

    Sirtinol is a specific SIRT1 and SIRT2 inhibitor with IC50 of 131 μM and 38 μM in cell-free assays, respectively.

    Features:Sirtinol does not inhibit class I and class II HDACs.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

Recently Viewed Items

Tags: buy SRT1720 | SRT1720 supplier | purchase SRT1720 | SRT1720 cost | SRT1720 manufacturer | order SRT1720 | SRT1720 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us